Company Overview

Light AI Inc. (traded in the U.S. on the OTC Markets under ticker OHCFF) is a medical technology company focused on the development of artificial intelligence–driven diagnostic tools that use optical imaging and data analytics to assist in the early detection of disease. The company operates within the digital health, medical diagnostics, and artificial intelligence in healthcare industries, with a stated emphasis on non-invasive screening technologies intended for use in clinical and point-of-care settings.

The company’s primary product development efforts center on proprietary optical imaging systems combined with machine-learning algorithms designed to analyze biological signals captured from human tissue. Light AI positions itself around early detection, workflow efficiency, and potential cost reduction for healthcare providers. Public disclosures indicate that the company evolved from earlier optical health research initiatives and later rebranded as Light AI Inc. to emphasize its artificial intelligence strategy. Details on commercialization timelines and scale of adoption remain limited in public filings, and some historical information is inconsistent across sources.

Business Operations

Light AI Inc.’s operations are primarily focused on research and development rather than large-scale commercial deployment. The company generates little to no recurring revenue based on publicly available disclosures, with activities centered on product validation, regulatory positioning, and intellectual property development. Operations are largely centralized, with no clearly delineated revenue-producing business segments disclosed in recent public records.

The company controls proprietary imaging technology and software algorithms intended for medical diagnostic use. Publicly available information does not consistently identify material subsidiaries, joint ventures, or revenue-sharing partnerships. Any commercialization efforts appear to be in early stages, and disclosures regarding manufacturing, distribution agreements, or healthcare system integration remain limited. Where operational details conflict across sources, data is inconclusive based on available public information.

Strategic Position & Investments

Strategically, Light AI Inc. positions itself within the growing intersection of AI-enabled diagnostics and preventive healthcare, targeting unmet needs in early disease detection. The company’s stated growth strategy emphasizes continued investment in technology development, clinical validation, and regulatory pathways, particularly in jurisdictions with established medical device approval frameworks.

There is no consistently verified public record of major acquisitions, large-scale equity investments, or ownership of operating portfolio companies. Capital allocation appears primarily directed toward internal development rather than external expansion. While Light AI references emerging technologies such as machine learning, optical spectroscopy, and data-driven clinical decision support, the extent of commercial readiness and market penetration remains uncertain based on public disclosures.

Geographic Footprint

Light AI Inc. is headquartered in North America, with corporate and development activities primarily associated with Canada and the United States. The company’s public filings and market disclosures indicate a limited physical operating footprint, with no confirmed large-scale international offices or production facilities.

Market focus appears to be on North American healthcare systems, with potential long-term interest in broader international markets. However, verifiable evidence of active operations, regulatory approvals, or material revenues outside North America is limited. International presence beyond exploratory or strategic planning stages cannot be conclusively confirmed from available public sources.

Leadership & Governance

Light AI Inc. is led by a small executive team overseeing corporate strategy, technology development, and regulatory planning. Public disclosures identify a chief executive officer and additional officers; however, executive titles, tenure, and responsibilities are not consistently reported across filings and market disclosures. As a result, some leadership details remain unclear.

• Data inconclusive based on available public sources – Executive leadership roles and complete governance structure cannot be independently verified with sufficient consistency across reputable sources.

The company’s leadership philosophy, as described in public communications, emphasizes innovation in medical diagnostics, responsible application of artificial intelligence, and long-term value creation through early disease detection technologies. Further governance details, including committee structures and independent director roles, are not consistently disclosed in accessible public documentation.